Cell & Gene Therapy Bioprocessing & Commercialization is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Chris Gemmiti, Ph.D.
VP Operations at Sentien Biotechnologies Inc.

Profile

Dr. Gemmiti has been active in the cell therapy field for more than 20 years, including roles at Wyss Institute at Harvard University and Organogenesis Inc. At Organogenesis, he led the Oral Regeneration business unit’s cross-functional, strategic alignment for the clinical development, regulatory submission-and-review and commercial launch of GINTUIT™, the first manufactured allogeneic cell therapy approved by BLA (2012). He holds a PhD in Biomedical Engineering from Georgia Institute of Technology and a BS in both Biomedical Engineering and Engineering Mechanics from Johns Hopkins University. At Georgia Tech, Dr. Gemmiti was an NSF Fellow in Entrepreneurship through the TI:GER Program. Dr. Gemmiti has served on the Advisory Boards of the Institute for Bioengineering and Bioscience (Georgia Tech), Biomedical Engineering (Johns Hopkins and Duke University), Tissue Engineering and Regenerative Medicine International Society (TERMIS) and Cell Therapy Bioprocessing.

Chris Gemmiti, Ph.D.'s Network

Agenda Sessions

  • Discussion Panel: Outsourcing vs. Insourcing – What is the best path to take?

    ,